-
Iran says US talks are on, as Trump warns supreme leader
-
Gaza health officials say strikes kill 24 after Israel says officer wounded
-
Empress's crown dropped in Louvre heist to be fully restored: museum
-
UK PM says Mandelson 'lied' about Epstein relations
-
Shai to miss NBA All-Star Game with abdominal strain
-
Trump suggests 'softer touch' needed on immigration
-
From 'flop' to Super Bowl favorite: Sam Darnold's second act
-
Man sentenced to life in prison for plotting to kill Trump in 2024
-
Native Americans on high alert over Minneapolis crackdown
-
Dallas deals Davis to Wizards in blockbuster NBA deal: report
-
Russia 'no longer bound' by nuclear arms limits as treaty with US ends
-
Panama hits back after China warns of 'heavy price' in ports row
-
Strike kills guerrillas as US, Colombia agree to target narco bosses
-
Wildfire smoke kills more than 24,000 Americans a year: study
-
Telegram founder slams Spain PM over under-16s social media ban
-
Curling kicks off sports programme at 2026 Winter Olympics
-
Preventative cholera vaccination resumes as global supply swells: WHO
-
Wales' Macleod ready for 'physical battle' against England in Six Nations
-
Xi calls for 'mutual respect' with Trump, hails ties with Putin
-
'All-time great': Maye's ambitions go beyond record Super Bowl bid
-
Shadow over Vonn as Shiffrin, Odermatt headline Olympic skiing
-
US seeks minerals trade zone in rare Trump move with allies
-
Ukraine says Abu Dhabi talks with Russia 'substantive and productive'
-
Brazil mine disaster victims in London to 'demand what is owed'
-
AI-fuelled tech stock selloff rolls on
-
Russia vows to act 'responsibly' as nuclear pact ends with US
-
White says time at Toulon has made him a better Scotland player
-
Washington Post announces 'painful' job cuts
-
All lights are go for Jalibert, says France's Dupont
-
Artist rubs out Meloni church fresco after controversy
-
Palestinians in Egypt torn on return to a Gaza with 'no future'
-
US removing 700 immigration officers from Minnesota
-
Who is behind the killing of late ruler Gaddafi's son, and why now?
-
Coach Thioune tasked with saving battling Bremen
-
Russia vows to act 'responsibly' once nuclear pact with US ends
-
Son of Norway's crown princess admits excesses but denies rape
-
US calls for minerals trade zone in rare move with allies
-
Vowles dismisses Williams 2026 title hopes as 'not realistic'
-
'Dinosaur' Glenn chasing skating gold in first Olympics
-
Gaza health officials say strikes kill 23 after Israel says shots wounded officer
-
Italy foils Russian cyberattacks targeting Olympics
-
Stocks stabilise after Wall St AI-fuelled sell-off
-
Figure skating favourite Malinin feeling 'the pressure' in Milan
-
Netflix film probes conviction of UK baby killer nurse
-
Timber hopes League Cup can be catalyst for Arsenal success
-
China calls EU 'discriminatory' over probe into energy giant Goldwind
-
Sales warning slams Ozempic maker Novo Nordisk's stock
-
Can Vonn defy ACL rupture to win Olympic medal?
-
Breakthrough or prelude to attack? What we know about Iran-US talks
-
German far-right MP detained over alleged Belarus sanctions breach
US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
K.AbuTaha--SF-PST